Method-dependent epidemiological cutoff values for detection of triazole resistance in Candida and Aspergillus species for the Sensititre Yeastone colorimetric broth and etest agar diffusion methods

Antimicrobial Agents and Chemotherapy

Volumn 63, Issue 1, 2019, Pages

  Espinel Ingroff, A ^a   Turnidge, J ^b   Alastruey Izquierdo, A ^c   Botterel, F ^d   Canton, E ^e   Castro, C ^f   Chen, Y C ^g   Chen, Y ^h   Chryssanthou, E ⁱ   Dannaoui, E ^j   Garcia Effron, G ^k   Gonzalez, G M ^l   Govender, N P ^m   Guinea, J ⁿ   Kidd, S ^o   Lackner, M ^p   Lass Florl C ^p   Linares Sicilia, M J ^q   Lopez Soria L ^r   Magobo, R ^j   Pelaez, T ^s   Quindos G ^t   Rodriguez Iglesia, M A ^u   Ruiz, M A ^v   Sanchez Reus F ^w   Sanguinetti, M ^x   Shields, R ^y   Szweda, P ^z   Tortorano, A ^aa   Wengenack, N L ^ab   Bramati, S ^ac   Cavanna, C ^ad   DeLuca, C ^ae   Gelmi, M ^af   Grancini, A ^ag   Lombardi, G ^ah   Meletiadis, J ^ai   Negri, C E ^aj   Passera, M ^ak   Peman, J ^al   Prigitano, A ^aa   Sala, E ^am   Tejada, M ^an   more..

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d Unité de Parasitologie   (France)

^e INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^f HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^g NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^h PUBLIC HEALTH ONTARIO   (Canada)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^j UNIVERSITÉ PARIS DESCARTES   (France)

^k UNIVERSIDAD NACIONAL DEL LITORAL   (Argentina)

^l UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^m UNIVERSITY OF THE WITWATERSRAND   (South Africa)

ⁿ HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^o SA Pathology   (Australia)

^p INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^q UNIVERSITY OF CÓRDOBA   (Spain)

^r HOSPITAL DE CRUCES   (Spain)

^s HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^t UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^u UNIVERSITY OF CÁDIZ   (Spain)

^v INSTITUTO DE INVESTIGACIÓN SANITARIA ARAGÓN IIS ARAGÓN   (Spain)

^w HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^x CATHOLIC UNIVERSITY   (Italy)

^y UNIVERSITY OF PITTSBURGH   (United States)

^z GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

^aa UNIVERSITY OF MILAN   (Italy)

^ab MAYO CLINIC ROCHESTER   (United States)

^ac SAN GERARDO HOSPITAL   (Italy)

^ad FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^ae HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^af SPEDALI CIVILI   (Italy)

^ag FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^ah OSPEDALE NIGUARDA CA GRANDA   (Italy)

^ai UNIVERSITY OF ATHENS   (Greece)

^aj FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^ak PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^al HOSPITAL UNIVERSITARIO LA FE   (Spain)

^am ASST Lariana General Hospital   (Italy)

^an IRCCS POLICLINICO SAN DONATO   (Italy)

more..

Author keywords

Antifungal resistance; Aspergillus spp; Candida albicans; Candida glabrata; Etest method ECVs; Etest MICs for fungal mutants; SYO method ECVs; SYO MICs for fungal mutants; Triazole ECVs

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT; TRIAZOLE DERIVATIVE;

AGAR DIFFUSION; ANTIFUNGAL RESISTANCE; ARTICLE; ASPERGILLUS FUMIGATUS; CANDIDA PARAPSILOSIS; CLAVISPORA LUSITANIAE; CONTROLLED STUDY; MEYEROZYMA GUILLIERMONDII; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PICHIA KUDRIAVZEVII; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; CLASSIFICATION; CLINICAL TRIAL; DISK DIFFUSION; DRUG EFFECT; HUMAN; IMMUNOCOMPROMISED PATIENT; ISOLATION AND PURIFICATION; MICROBIOLOGY; MULTICENTER STUDY;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; DISK DIFFUSION ANTIMICROBIAL TESTS; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; HUMANS; IMMUNOCOMPROMISED HOST; ITRACONAZOLE; TRIAZOLES; VORICONAZOLE;

EID: 85058915233     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01651-18     Document Type: Article

References (38)

1. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. 2016. Clinical practice guidelines for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 62:1–50. https://doi.org/10.1093/cid/civ747.
2. Patterson TF, Thompson GR, III, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE. 2016. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 63:e1–e60. https://doi.org/10.1093/cid/ciw326.
3. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Cast-agnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Flörl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ, ESCMID Fungal Infection Study Group. 2012. ESCMID guidelines for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18:19–37. https://doi.org/10.1111/1469-0691.12039.
4. Klingspor L, Saaedi B, Ljungman P, Szakos A. 2015. Epidemiology and outcomes of patients with invasive mould infections: a retrospective observational study from a single centre (2005-2009). Mycoses 58: 470–477. https://doi.org/10.1111/myc.12344.
5. Kosmidis C, Denning DW. 2015. The clinical spectrum of pulmonary aspergillosis. Thorax 70:270–277. https://doi.org/10.1136/thoraxjnl-2014-206291.
6. Berkow EL, Lockhart SR. 2017. Fluconazole resistance in Candida species: a current perspective. Infect Drug Resist 10:237–245. https://doi.org/10.2147/IDR.S118892.
7. Vale-Silva LA, Moeckli B, Torelli R, Posteraro B, Sanguinetti M, Sanglard D. 2016. Upregulation of the adhesin gene EPA1 mediated by PDR1 in Candida glabrata leads to enhanced host colonization. mSphere 1:e00065-15. https://doi.org/10.1128/mSphere.00065-15.
8. Sanglard D, Coste AT. 2016. Activity of isavuconazole and other azoles against Candida clinical isolates and yeast model systems with known azole resistance mechanisms. Antimicrob Agents Chemother 60: 229–238. https://doi.org/10.1128/AAC.02157-15.
9. Forastiero A, Mesa-Arango AC, Alastruey-Izquierdo A, Alcazar-Fuoli L, Bernal-Martinez L, Pelaez T, Lopez JF, Grimalt JO, Gomez-Lopez A, Cuesta I, Zaragoza O, Mellado E. 2013. Candida tropicalis antifungal cross-resistance is related to different azole target (Erg11p) modifications. Antimicrob Agents Chemother 57:4769 – 4781. https://doi.org/10.1128/AAC.00477-13.
10. Bernal-Martínez L, Gil H, Rivero-Menéndez O, Gago S, Cuenca-Estrella M, Mellado E, Alastruey-Izquierdo A. 2017. Development and validation of a high resolution melting assay to detect azole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 61:e01083-17. https://doi.org/ 10.1128/AAC.01083-17.
11. Clinical and Laboratory Standards Institute. 2017. Reference method for broth dilution antifungal susceptibility testing of yeasts, 4th ed. CLSI standard M27. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Clinical and Laboratory Standards Institute. 2017. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, 3rd ed. CLSI standard M38. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Arendrup MC, Meletiadis J, Mouton JW, Guinea J, Cuenca-Estrella M, Lagrou K, Howard SJ, Arendrup MC, Meletiadis J, Howard SJ, Mouton J, Guinea J, Lagrou K, Arikan-Akdagli S, Barchiesi F, Hamal P, Järv H, Lass-Flörl C, Mares M, Matos T, Muehlethaler K, Rogers TR, Torp Andersen C, Verweij P, Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing. 2016. EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents. Clin Infect Dis 22: 571.e1–571.e4. https://doi.org/10.1016/j.cmi.2016.01.017.
14. Trek Diagnostic Systems. 2012. Sensititre Yeast One: Yeast One susceptibility, v1.8. Trek Diagnostic Systems, Cleveland, OH.
15. bioMérieux SA. 2013. Etest antifungal susceptibility testing package insert. bioMérieux SA, Marcy-l’Etoile, France.
16. bioMérieux SA. 2013. Etest performance, interpretative criteria and quality control ranges table. bioMérieux SA, Marcy-l’Etoile, France.
17. Pfaller MA, Espinel-Ingroff A, Jones RN. 2004. Clinical evaluation of Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole. J Clin Microbiol 42:4577–4580. https://doi.org/10.1128/JCM.42.10.4577-4580.2004.
18. Espinel-Ingroff A, Pfaller M, Erwin ME, Jones RN. 1996. Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents using a Casitone agar and solidified RPMI 1640 medium with 2% glucose. J Clin Microbiol 34: 848–885. https://doi.org/10.1128/JCM.40.6.2101-2107.2002.
19. Espinel-Ingroff A, Rezuzta A. 2002. E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method. J Clin Microbiol 40:2001–2107.
20. Burgel P-R, Baixench M-T, Amsellem M, Audureau E, Chapron J, Kanaan R, Honoré I, Dupouy-Camet J, Dusser D, Klaassen CH, Meis JF, Hubert D, Paugam A. 2012. High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob Agents Chemother 56:869 – 874. https://doi.org/10.1128/AAC.05077-11.
21. Wu C-J, Wang H-C, Lee J-C, Lo H-J, Dai C-T, Chou P-H, Ko W-C, Chen Y-C. 2015. Azole-resistant Aspergillus fumigatus isolates carrying TR34/L98H mutations in Taiwan. Mycoses 58:544–549. https://doi.org/10.1111/myc .12354.
22. Mello E, Posteraro B, Vella A, De Carolis E, Torelli R, D’Inzeo T, Verweij PE, Sanguinetti M. 2017. Susceptibility testing of common and uncommon Aspergillus species against posaconazole and other mold-active antifungal azoles using the Sensititre method. Antimicrob Agents Chemother 61:e00168-17. https://doi.org/10.1128/AAC.00168-17.
23. Espinel-Ingroff A, Turnidge J, Alastruey-Izquierdo A, Dannaoui E, Garcia-Effron G, Guinea J, Kidd S, Pelaez T, Sanguinetti M, Meletiadis J, Botterel F, Bustamante B, Chen Y-C, Chakrabarti A, Chowdhary A, Chryssanthou E, Córdoba S, Gonzalez GM, Guarro J, Johnson EM, Kus JV, Lass-Flörl C, Linares-Sicilia MJ, Martín-Mazuelos E, Negri CE, Pfaller MA, Tortorano AM. 2018. Posaconazole MIC distributions for Aspergillus fumigatus species complex by four methods: impact of cyp51A mutations on estimation of epidemiological cutoff values. Antimicrob Agents Chemother 62:e01916-17. https://doi.org/10.1128/AAC.01916-17.
24. Szweda P, Gucwa K, Romanowska E, Dzierzanowska-Fangrat K, Naumiuk Ł, Brillowska-Dabrowska A, Wojciechowska-Koszko I, Milewski S. 2015. Mechanisms of azole resistance among clinical isolates of Candida glabrata in Poland. J Med Microbiol 64:610–619. https://doi.org/10.1099/jmm.0.000062.
25. Espinel-Ingroff A, Arendrup M, Cantón E, Cordoba S, Dannaoui E, García-Rodríguez J, Gonzalez GM, Govender NP, Martin-Mazuelos E, Lackner M, Lass-Flörl C, Linares Sicilia MJ, Rodriguez-Iglesias MA, Pelaez T, Shields RK, Garcia-Effron G, Guinea J, Sanguinetti M, Turnidge J. 2017. Multi-center study of method-dependent epidemiological cutoff values for detection of resistance in Candida spp. and Aspergillus spp. to amphotericin B and echinocandins for the Etest agar diffusion method. Antimicrob Agents Chemother 61:e01792-16. https://doi.org/10.1128/AAC.01792-16.
26. Clinical and Laboratory Standards Institute. 2018. Epidemiological cutoff values for antifungal susceptibility testing. CLSI supplement M59, 2nd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
27. Clinical and Laboratory Standards Institute. 2016. Principles and procedures for the development of epidemiological cutoff values for antifungal susceptibility testing. CLSI M57 document, 1st ed. Clinical and Laboratory Standards Institute, Wayne, PA.
28. Espinel-Ingroff A, Turnidge J. 2016. The role of epidemiological cutoff values (ECVs/ECOFFs) in antifungal susceptibility testing and interpretation for uncommon yeasts and moulds. Rev Iberoam Micol 33:63–75. https://doi.org/10.1016/j.riam.2016.04.001.
29. Turnidge J, Kahlmeter G, Kronvall G. 2006. Statistical characterization of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect 12:418 – 425. https://doi.org/10.1111/j.1469-0691.2006.01377.x.
30. Meletiadis J, Curfs-Breuker I, Meis JF, Mouton JW. 2017. In vitro antifungal susceptibility testing of Candida isolates with the EUCAST methodology, a new method for ECOFF determination. Antimicrob Agents Chemother 61:e02372-16. https://doi.org/10.1128/AAC.02372-16.
31. Alastruey-Izquierdo A, Alcazar-Fuoli L, Cuenca-Estrella M. 2014. Antifungal susceptibility profile of cryptic species of Aspergillus. Mycopathologia 178:427– 433. https://doi.org/10.1007/s11046-014-9775-z.
32. Howell S, Hazen KC. 2011. Candida, Cryptococcus and other yeasts of medical importance. In Versalovic J, Carroll KC, Funke G, Jorgensen JH, Landry ML, Warnock DW (ed), Manual of clinical microbiology, 10th ed. ASM Press, Washington, DC.
33. Chau AS, Mendrick CA, Sabatelli FL, Loebenberg D, McNicholas PM. 2004. Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother 48:2124–2131. https://doi.org/10.1128/AAC.48.6.2124-2131.2004.
34. Morio F, Loge C, Besse B, Hennequin C, Le Pape P. 2010. Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Diagn Microbiol Infect Dis 66:373–384. https://doi.org/10.1016/j.diagmicrobio.2009.11.006.
35. Flowers SA, Brendan CB, Whaley SG, Schuler MA, Rogers D. 2015. Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans. Antimicrob Agents Chemother 59:450–460. https://doi.org/10.1128/AAC.03470-14.
36. Rivero-Menendez O, Alastruey-Izquierdo A, Mellado E, Cuenca-Estrella M. 2016. Triazole resistance in Aspergillus spp.: a worldwide problem? J Fungi 2:21. https://doi.org/10.3390/jof2030021.
37. Garcia-Effron G, Dilger A, Alcazar-Fuoli L, Park S, Mellado E, Perlin DS. 2008. Rapid detection of triazole antifungal resistance in Aspergillus fumigatus. J Clin Microbiol 46:1200–1206. https://doi.org/10.1128/JCM.02330-07.
38. Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G. 2005. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother 49:668–679. https://doi.org/10.1128/AAC.49.2.668-679.2005.